Politics, Policy & Law
Drug pricing pressure; plus European deal trends
BioCentury’s latest podcast also features Brii’s IPO and the latest in Aduhelm
The ball’s in HHS’s court as the Biden administration ramps up pressure on Congress to act on drug pricing. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the White House’s initiative against high drug prices as well as paying for Biogen’s Alzheimer’s therapy, biopharma trends from Europe and why Brii chose Hong Kong for its IPO.
An executive order released last week from President Joe Biden that seeks to promote competition among U.S. businesses includes a near-term deadline for HHS to develop a plan to take on drug prices.
BioCentury Washington Editor Steve Usdin believes that the agency will likely look to CMS’s Centers for Medicare & Medicaid Services to come up with a plan to tackle drug prices. He also argues that a big part of the White House’s reason to put the topic back in the spotlight is to spur Congress to act while giving the administration a few tools in its back pocket.
Usdin says the policies proposed by Biden that industry will be more likely to support are “the kinds of things that go after violations of what BioCentury has called the social contract.” Examples, he says, include “evergreening” drugs or attempts to block biosimilar competition.